| 1. |
- Bluhm, Marcus, et al.
(författare)
-
Dynamics of critical fluctuations : Theory - phenomenology - heavy-ion collisions
- 2020
-
Ingår i: Nuclear Physics A. - : ELSEVIER. - 0375-9474 .- 1873-1554. ; 1003
-
Tidskriftsartikel (refereegranskat)abstract
- This report summarizes the presentations and discussions during the Rapid Reaction Task Force "Dynamics of critical fluctuations: Theory - phenomenology - heavy-ion collisions", which was organized by the ExtreMe Matter Institute EMMI and held at GSI, Darmstadt, Germany in April 2019. We address the current understanding of the dynamics of critical fluctuations in QCD and their measurement in heavy-ion collision experiments. In addition, we outline what might be learned from studying correlations in other physical systems, such as cold atomic gases.
|
|
| 2. |
- Arab, Khelifa, et al.
(författare)
-
Long Noncoding RNA TARID Directs Demethylation and Activation of the Tumor Suppressor TCF21 via GADD45A
- 2014
-
Ingår i: Molecular Cell. - : Elsevier BV. - 1097-2765 .- 1097-4164. ; 55:4, s. 604-614
-
Tidskriftsartikel (refereegranskat)abstract
- DNA methylation is a dynamic and reversible process that governs gene expression during development and disease. Several examples of active DNA demethylation have been documented, involving genome-wide and gene-specific DNA demethylation. How demethylating enzymes are targeted to specific genomic loci remains largely unknown. We show that an antisense lncRNA, termed TARID (for TCF21 antisense RNA inducing demethylation), activates TCF21 expression by inducing promoter demethylation. TARID interacts with both the TCF21 promoter and GADD45A (growth arrest and DNA-damage-inducible, alpha), a regulator of DNA demethylation. GADD45A in turn recruits thymine-DNA glycosylase for base excision repair-mediated demethylation involving oxidation of 5-methylcytosine to 5-hydroxymethylcytosine in the TCF21 promoter by ten-eleven translocation methylcytosine dioxygenase proteins. The results reveal a function of lncRNAs, serving as a genomic address label for GADD45A-mediated demethylation of specific target genes.
|
|
| 3. |
- Gerbitz, Armin, et al.
(författare)
-
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation : results from the randomized phase I/IIa MULTIVIR-01 study
- 2023
-
Ingår i: Frontiers in Immunology. - : Frontiers Media S.A.. - 1664-3224. ; 14
-
Tidskriftsartikel (refereegranskat)abstract
- IntroductionAllogeneic stem cell transplantation is used to cure hematologic malignancies or deficiencies of the hematopoietic system. It is associated with severe immunodeficiency of the host early after transplant and therefore early reactivation of latent herpesviruses such as CMV and EBV within the first 100 days are frequent. Small studies and case series indicated that application of herpes virus specific T cells can control and prevent disease in this patient population.MethodsWe report the results of a randomized controlled multi centre phase I/IIa study (MULTIVIR-01) using a newly developed T cell product with specificity for CMV and EBV derived from the allogeneic stem cell grafts used for transplantation. The study aimed at prevention and preemptive treatment of both viruses in patients after allogeneic stem cell transplantation targeting first infusion on day +30. Primary endpoints were acute transfusion reaction and acute-graft versus-host-disease after infusion of activated T cells.ResultsThirty-three patients were screened and 9 patients were treated with a total of 25 doses of the T cell product. We show that central manufacturing can be achieved successfully under study conditions and the product can be applied without major side effects. Overall survival, transplant related mortality, cumulative incidence of graft versus host disease and number of severe adverse events were not different between treatment and control groups. Expansion of CMV/EBV specific T cells was observed in a fraction of patients, but overall there was no difference in virus reactivation.DiscussionOur study results indicate peptide stimulated epitope specific T cells derived from stem cell grafts can be administered safely for prevention and preemptive treatment of reactivation without evidence for induction of acute graft versus host disease.Clinical trial registrationhttps://clinicaltrials.gov, identifier NCT02227641.
|
|
| 4. |
- Herold, Sebastian, et al.
(författare)
-
Towards Improving Software Architecture Degradation Mitigation by Machine Learning
- 2020
-
Konferensbidrag (refereegranskat)abstract
- Mitigating software architecture degradation is a task in evolving large and complex software-intensive systems that is as important as it is challenging. One aspect adding to the complexity of the task is the amount of information in the implementations of most real-world systems to be digested in order to detect, analyse, and remedy degradation. In domains with similar challenges, machine learning techniques have been applied in recent years and partially delivered exciting results. Hence the question arises whether, and to which degree, machine learning can be successfully applied to tackle software architecture degradation. In this paper, we propose a novel combination of existing techniques for different phases of the task of mitigating software architecture degradation from detecting it to repairing it. We outline how these techniques could be complemented by machine learning to increase their accuracy and efficiency over time
|
|
| 5. |
- Illini, Oliver, et al.
(författare)
-
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
- 2024
-
Ingår i: International Journal of Molecular Sciences. - : MDPI. - 1661-6596 .- 1422-0067. ; 25:7
-
Tidskriftsartikel (refereegranskat)abstract
- EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab. Data from 86 patients with a median age of 67 years and a median of two prior lines of treatment were analyzed. Treatment-related adverse events (TRAEs) occurred in 95% of patients. Grade >= 3 TRAEs were reported in 38% of patients and included diarrhea (22%) and rash (8%). In 17% of patients, therapy was permanently discontinued, and two patients died due to TRAEs. Women were seven times more likely to discontinue treatment than men. In the overall cohort, the objective response rate to mobocertinib was 34% (95% CI, 24-45). The response rate in treatment-naive patients was 27% (95% CI, 8-58). The median progression-free and overall survival was 5 months (95% CI, 3.5-6.5) and 12 months (95% CI, 6.8-17.2), respectively. The intracranial response rate was limited (13%), and one-third of disease progression cases involved the brain. Mobocertinib also showed antitumor activity following EGFR Ex20-specific therapy and vice versa. Potential mechanisms of resistance to mobocertinib included amplifications in MET, PIK3CA, and NRAS. Mobocertinib demonstrated meaningful efficacy in a real-world setting but was associated with considerable gastrointestinal and cutaneous toxicity.
|
|
| 6. |
- Nahrgang, Marlene, et al.
(författare)
-
Nonequilibrium chiral fluid dynamics including dissipation and noise
- 2011
-
Ingår i: Physical Review C. Nuclear Physics. - 0556-2813 .- 1089-490X. ; 84:2, s. 024912-
-
Tidskriftsartikel (refereegranskat)abstract
- We present a consistent theoretical approach for the study of nonequilibrium effects in chiral fluid dynamics within the framework of the linear sigma model with constituent quarks. Treating the quarks as an equilibrated heat bath, we use the influence functional formalism to obtain a Langevin equation for the sigma field. This allows us to calculate the explicit form of the damping coefficient and the noise correlators. For a self-consistent derivation of both the dynamics of the sigma field and the quark fluid, we have to employ the 2PI (two-particle irreducible) effective action formalism. The energy dissipation from the field to the fluid is treated in the exact formalism of the 2PI effective action where a conserved energy-momentum tensor can be constructed. We derive its form and comment on approximations generating additional terms in the energy-momentum balance of the entire system.
|
|
| 7. |
- Nahrgang, Marlene, et al.
(författare)
-
The impact of dissipation and noise on fluctuations in chiral fluid dynamics
- 2013
-
Ingår i: Journal of Physics G. - : IOP Publishing. - 0954-3899 .- 1361-6471. ; 40:5, s. 055108-
-
Tidskriftsartikel (refereegranskat)abstract
- We investigate the nonequilibrium evolution of the sigma field coupled to a fluid dynamic expansion of a hot fireball to model the chiral phase transition in heavy-ion collisions. The dissipative processes and fluctuations are allowed under the assumption that the total energy of the coupled system is conserved. We use the linear sigma model with constituent quarks to investigate the effects of the chiral phase transition on the equilibration and excitation of the sigma modes. The quark fluid acts as a heat bath in local thermal equilibrium and the sigma field evolves according to a semiclassical stochastic Langevin equation of motion. The effects of supercooling and reheating of the fluid in a first order phase transition are observed via the delayed relaxation of the sigma field to a new equilibrium state. At the first order phase transition the nonequilibrium fluctuations are strongly enhanced.
|
|
| 8. |
- Schramm, Christoph, et al.
(författare)
-
Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry.
- 2010
-
Ingår i: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. - : Ovid Technologies (Wolters Kluwer Health). - 1527-6473. ; 16:4, s. 461-9
-
Tidskriftsartikel (refereegranskat)abstract
- The principal aim of this study was to compare the probability of and potential risk factors for death and graft loss after primary adult and pediatric liver transplantation in patients undergoing transplantation for autoimmune hepatitis (AIH) to those in patients undergoing transplantation for primary biliary cirrhosis (PBC; used as the reference group) or alcoholic cirrhosis (used as an example of a nonautoimmune liver disease). The 5-year survival of patients undergoing transplantation for AIH (n = 827) was 0.73 [95% confidence interval (CI) = 0.67-0.77]. This was similar to that of patients undergoing transplantation for alcoholic cirrhosis (0.74, 95% CI = 0.72-0.76, n = 6424) but significantly worse than that of patients undergoing transplantation for PBC (0.83, 95% CI = 0.80-0.85, n = 1588). Fatal infectious complications occurred at an increased rate in patients with AIH (hazard ratio = 1.8, P = 0.002 with PBC as the reference). The outcome of pediatric AIH patients was similar to that of adult patients undergoing transplantation up to the age of 50 years. However, the survival of AIH patients undergoing transplantation beyond the age of 50 years (0.61 at 5 years, 95% CI = 0.51-0.70) was significantly reduced in comparison with the survival of young adult AIH patients (0.78 at 18-34 years, 95% CI = 0.70-0.86) and in comparison with the survival of patients of the same age group with PBC or alcoholic cirrhosis. In conclusion, age significantly affects patient survival after liver transplantation for AIH. The increased risk of dying of infectious complications in the early postoperative period, especially above the age of 50 years, should be acknowledged in the management of AIH patients with advanced-stage liver disease who are listed for liver transplantation. It should be noted that not all risk factors relevant to patient and graft survival could be analyzed with the European Liver Transplant Registry database.
|
|
